UNITY Biotechnology, Inc. Announces Plan for Phase 2 Clinical Study of UBX0101 in Osteoarthritis of the Knee
30 juil. 2019 16h30 HE
|
Unity Biotechnology, Inc.
SAN FRANCISCO, July 30, 2019 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing...
UNITY Biotechnology, Inc. To Announce Second Quarter 2019 Financial Results
30 juil. 2019 08h00 HE
|
Unity Biotechnology, Inc.
SAN FRANCISCO, July 30, 2019 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing...
UNITY Biotechnology Reports Promising Topline Data from Phase 1 First-in-human Study of UBX0101 in Patients with Osteoarthritis of the Knee
18 juin 2019 07h00 HE
|
Unity Biotechnology, Inc.
Clinical results support senescent cell elimination with UBX0101 as a potential treatment for osteoarthritis Topline results demonstrate a dose-dependent and clinically meaningful impact on pain ...
UNITY Biotechnology, Inc. and UCSF Enter Exclusive License Agreement on alpha-Klotho Protein for the Treatment of Age-Related Cognitive Decline
29 mai 2019 16h05 HE
|
Unity Biotechnology, Inc.
SAN FRANCISCO, May 29, 2019 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) (NASDAQ:UBX), a biotechnology company developing therapeutics to extend healthspan by slowing, halting or...
UNITY Biotechnology, Inc. to Present at Upcoming Investor Conferences
23 mai 2019 16h01 HE
|
Unity Biotechnology, Inc.
SAN FRANCISCO, May 23, 2019 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or...
UNITY Biotechnology, Inc. Reports First Quarter 2019 Financial Results
08 mai 2019 16h05 HE
|
Unity Biotechnology, Inc.
SAN FRANCISCO, May 08, 2019 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or...
UNITY Biotechnology, Inc. to Announce First Quarter 2019 Financial Results
29 avr. 2019 16h05 HE
|
Unity Biotechnology, Inc.
SAN FRANCISCO, April 29, 2019 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or...
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2018 Financial Results and Program Updates
06 mars 2019 08h00 HE
|
Unity Biotechnology, Inc.
SAN FRANCISCO, March 06, 2019 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or...
UNITY Biotechnology, Inc. to Participate in the Cowen 39th Annual Health Care Conference
04 mars 2019 16h05 HE
|
Unity Biotechnology, Inc.
SAN FRANCISCO, March 04, 2019 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or...
CORRECTING and REPLACING -- UNITY Biotechnology, Inc. to Announce Fourth Quarter and Full Year 2018 Financial Results
27 févr. 2019 16h05 HE
|
Unity Biotechnology, Inc.
SAN FRANCISCO, Feb. 27, 2019 (GLOBE NEWSWIRE) -- In a release issued under the same headline on February 25th by UNITY Biotechnology, Inc. [Nasdaq: UBX], please note that in the first paragraph of...